Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Composite Copy Number Variation in CDK4 , CDKN2A and RB1 Predisposes Mantle Cell Lymphoma to Expansion of PD1+ Tumor Cells and Resistance to CDK4/6 Inhibitor Therapy as Revealed by Integrative Longitudinal scRNA-seq

Maurizio Di Liberto, PhD, Yang Hu, PhD, Xiangao Huang, PhD, Christina Y. Lee, MD, Kevin Wang, B.S., Nancy L. Bartlett, MD, LeAnn Ridling, Kristie A. Blum, MD, Kami J. Maddocks, MD, Steven I Park, MD, Jia Ruan, MD PhD, Kenneth Eng, B.S., Lorenzo Galluzzi, PhD, John P. Leonard, MD, Peter Martin, FRCPC, MD MS, Olivier Elemento, PhD, Selina Chen-Kiang, PhD

Blood (2019) 134 (Supplement_1): 1492.

https://doi.org/10.1182/blood-2019-130944

Published: 2019

Journal Articles

Disrupting GRINL1A Association with Cereblon Accelerates IKZF1/3 Degradation and IMiD Killing of Mantle Cell Lymphoma Cells By CDK4/6 Inhibition

Nicole Zhao, Maurizio Di Liberto, PhD, Olivier Elemento, PhD, Selina Chen-Kiang, PhD, Xiangao Huang, PhD

Blood (2019) 134 (Supplement_1): 299.

https://doi.org/10.1182/blood-2019-128927

Published: 2019

Journal Articles

PRMT5 Inhibition Drives Therapeutic Vulnerability to BCL-2 Inhibition with Venetoclax and Provides Rationale for Combination Therapy in Mantle Cell Lymphoma

Fiona Brown, BS, Yang Zhang, PhD, Claire Hinterschied, Alexander Prouty, BS, Shelby Sloan, BS, JoBeth Helmig-Mason, Msc, Ji Hyun Chung, PhD, Kris Vaddi, PhD, Selina Chen-Kiang, PhD, Maurizio Di Liberto, PhD, Lapo Alinari, MD PhD, Peggy Scherle, PhD, Rosa Lapalombella, PhD, Jihye Paik, PhD, Robert A Baiocchi, MD PhD

Blood (2019) 134 (Supplement_1): 302.

https://doi.org/10.1182/blood-2019-130797

Published: 2019

Journal Articles

T-Cell Clonal Expansion and Activation Associated with Durable Clinical Response to Dual BTK and CDK4/6 Inhibitor Therapy in Mantle Cell Lymphoma

Christina Y. Lee, MD, Maurizio Di Liberto, PhD, Yang Hu, PhD, Xiangao Huang, PhD, Nancy L Bartlett, MD, Kami J. Maddocks, MD, John P. Leonard, MD, Nils-Petter Rudqvist, PhD, Lorenzo Galluzzi, PhD, Peter Martin, FRCPC, MD MS, Olivier Elemento, PhD, Selina Chen-Kiang, PhD

Blood (2019) 134 (Supplement_1): 3973.

https://doi.org/10.1182/blood-2019-122322

Published: 2019

Journal Articles

Targeting PRMT5 to Circumvent Acquired Ibrutinib Resistance in Mantle Cell Lymphoma

Shelby Sloan, BS, Fiona Brown, BS, JI Hyun Chung, PhD, Alexander Prouty, BS, Esther Wheeler, BS, Bonnie K Harrington, DVM, PhD, Eric Brooks, BS, Ayse S Yilmaz, MS, Hatice G Ozer, PhD, John C. Byrd, MD, Selina Chen-Kiang, PhD, Maurizio Di Liberto, PhD, Rosa Lapalombella, PhD, Kris Vaddi, PhD, Peggy Scherle, PhD, Youssef Youssef, MD, Robert A Baiocchi, MD PhD, Lapo Alinari, MD PhD

Blood (2019) 134 (Supplement_1): 4065.

https://doi.org/10.1182/blood-2019-128998

Published: 2019

Journal Articles

Cooperative Repression of IRF4 and Induction of IRF7 By CDK4/6 Inhibition Sensitizes Mantle Cell Lymphoma Cells to IMiD-Mediated Apoptosis Independent of p16 Deletion or c-Myc Overexpression

Basel A Humos, Maurizio Di Liberto, PhD, Xiangao Huang, PhD, Olivier Elemento, PhD, Selina Chen-Kiang, PhD

Blood (2018) 132 (Supplement 1): 2864.

https://doi.org/10.1182/blood-2018-99-117487

Published: 2018

Journal Articles

A Phase I Trial of Ibrutinib Plus Palbociclib in Patients with Previously Treated Mantle Cell Lymphoma

Peter Martin, MD, Kristie Blum, MD, Nancy L. Bartlett, MD, Steven I. Park, MD, Kami J. Maddocks, MD, Jia Ruan, MD PhD, Maurizio Di Liberto, PhD, Xiangao Huang, PhD, Giorgio Inghirami, MD, Pamela Harris, MD, Selina Chen-Kiang, PhD, John P. Leonard, MD

Blood (2016) 128 (22): 150.

https://doi.org/10.1182/blood.V128.22.150.150

Published: 2016

Journal Articles

PIK3IP1 Inhibition of PI3K in G1 Arrest Induced By CDK4 Inhibition Reprograms MCL for Ibrutinib Therapy

Maurizio Di Liberto, PhD, Xiangao Huang, PhD, Olivier Elemento, PhD, Ken Eng, Kristie A. Blum, MD, Nancy L. Bartlett, MD, Steven I. Park, MD, Jia Ruan, MD PhD, Kami J. Maddocks, MD, Giorgio Inghirami, MD, Lewis Cantley, MD, John P. Leonard, MD, Peter Martin, MD, Selina Chen-Kiang, PhD

Blood (2016) 128 (22): 610.

https://doi.org/10.1182/blood.V128.22.610.610

Published: 2016

Journal Articles

High-Dose Carfilzomib and Dexamethasone As First-Line Treatment in Symptomatic Multiple Myeloma

Tomer M Mark, MD MSc, Sujitha Yadlapati, MBBS, Lyubov Neglyad, Jennifer Bourke, RN, David Jayabalan, BSMS, MSc, Adriana C Rossi, MD, Roger N Pearse, MD PhD, Arthur Perry, PA, Karen Pekle, NP, Kathleen Pogonowski, RN, Linda Tegnestam, RN, Xiangao Huang, PhD, Maurizio Di Liberto, PhD, Scott Ely, MD MPH, Morton Coleman, MD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2015) 126 (23): 4258.

https://doi.org/10.1182/blood.V126.23.4258.4258

Published: 2015

Journal Articles

Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma Overcomes Negative Prognostic Impact of Adverse Cytogenetics and Prior Resistance to Lenalidomide and Bortezomib

Tomer M Mark, MD MSc, Angelique Boyer, Sujitha Yadlapati, MBBS, Adriana C Rossi, MD, Roger N Pearse, MD PhD, Karen Pekle, NP, Arthur Perry, PA, Kathleen Pogonowski, RN, Ekta Aneja, MD, Linda Tegnestam, RN, David Jayabalan, BSMS, MSc, Scott Ely, MD MPH, Morton Coleman, MD, Xiangao Huang, PhD, Maurizio Di Liberto, PhD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2015) 126 (23): 4232.

https://doi.org/10.1182/blood.V126.23.4232.4232

Published: 2015

Journal Articles

Inhibition of CDK4/CDK6 Sensitizes Myeloma to IMiD By Reducing the MEIS2 to Cereblon Ratio That Accelerates IKZF1 and IKZF3 Degradation

Xiangao Huang, PhD, David Jayabalan, BSMS, MSc, Maurizio Di Liberto, PhD, Zhengming Chen, PhD, Anna C Schinzel, PhD, Scott Ely, MD MPH, Adriana C Rossi, MD MHS, Roger N Pearse, MD PhD, Ekta Aneja, MBBS, Morton Coleman, MD, Joseph M Lane, MD, William C. Hahn, MD PhD, Tomer M Mark, MD MSc, Ruben Niesvizky, MD, Selina Chen-Kiang, PhD

Blood (2015) 126 (23): 500.

https://doi.org/10.1182/blood.V126.23.500.500

Published: 2015

Journal Articles

Sensitizing shRNA Screen for Molecular Targets in CDK4/CDK6-Based Combination Therapy in Multiple Myeloma

Xiangao Huang, PhD, Maurizio Di Liberto, PhD, David Chiron, PhD, Ruben Niesvizky, MD, Anna C. Schinzel, PhD, William C. Hahn, MD PhD, Selina Chen-Kiang, PhD

Blood (2014) 124 (21): 3440.

https://doi.org/10.1182/blood.V124.21.3440.3440

Published: 2014

Journal Articles

Poor Overall Survival of Patients with Ibrutinib-Resistant Mantle Cell Lymphoma

Peter Martin, MD, Kami J. Maddocks, MD, Katherine Noto, Beth Christian, MD, Richard R. Furman, MD, Leslie A. Andritsos, MD, Joseph M Flynn, D.O., MPH, Jeffrey A. Jones, MD, Jia Ruan, MD PhD, Selina Chen-Kiang, PhD, Maurizio Di Liberto, PhD, John P. Leonard, MD, Kristie A. Blum, MD

Blood (2014) 124 (21): 3047.

https://doi.org/10.1182/blood.V124.21.3047.3047

Published: 2014

Journal Articles

Protein Arginine Methyltransferase 5 Directly Targets and Epigenetically Silences microRNAs miR33b and miR96 to Support Constitutive Cyclin D1 Activity in Non-Hodgkin’s Lymphoma

Vrajesh Karkhanis, PhD, Olivier Elemento, PhD, Maurizio Di Liberto, PhD, Selina Chen-Kiang, PhD, Said Sif, PhD, Robert A. Baiocchi, MD PhD

Blood (2014) 124 (21): 60.

https://doi.org/10.1182/blood.V124.21.60.60

Published: 2014

Journal Articles

Selective inhibition of CDK4/CDK6 sensitizes bone marrow myeloma cells for killing by proteasome inhibitors carfilzomib and PR-047 through cell cycle-dependent expression of pro-apoptotic Noxa and Bim.

Maurizio Di Liberto, PhD, Xiangao Huang, PhD, Rediet Zewdu, B.S., Francesco Parlati, PhD, Monette Aujay, B.S., Ruben Niesvizky, MD, Selina Chen-Kiang, PhD

Blood (2009) 114 (22): 2854.

https://doi.org/10.1182/blood.V114.22.2854.2854

Published: 2009

Journal Articles

Induction of sequential G1 arrest and synchronous S phase entry by reversible CDK4/CDK6 inhibition sensitizes myeloma cells for cytotoxic killing through loss of IRF-4.

Xiangao Huang, PhD, Maurizio Di Liberto, PhD, Scott Ely, MD, MPH, David S Jayabalan, BSMS, Isan Chen, MD, Keith D. Wilner, PhD, Malcolm Moore, DPhil, Ruben Niesvizky, MD, Selina Chen-Kiang, PhD

Blood (2009) 114 (22): 299.

https://doi.org/10.1182/blood.V114.22.299.299

Published: 2009

Journal Articles

Induction of Sustained Early G1 Arrest by Selective Inhibition of CDK4 and CDK6 Primes Myeloma Cells for Synergistic Killing by Proteasome Inhibitors Carfilzomib and PR-047

Xiangao Huang, PhD, Kathryn Bailey, Maurizio Di Liberto, PhD, Francesco Parlati, PhD, Ruben Niesvizky, MD, Susan Demo, PhD, Selina Chen-Kiang, PhD

Blood (2008) 112 (11): 3670.

https://doi.org/10.1182/blood.V112.11.3670.3670

Published: 2008

Journal Articles

Selective Inhibition of CDK4 and CDK6 Primes Chemoresistant Myeloma Cell for Cytotoxic Killing through Induction of Cell Cycle-Coupled Mitochondrial Dysfunction and Apoptosis

Xiangao Huang, PhD, Maurizio Di Liberto, PhD, Tracey Louie, B.Sc., David S Jayabalan, B.Sc., Scott Ely, MD, MPH, Ruben Niesvizky, MD, Selina Chen-Kiang, PhD

Blood (2008) 112 (11): 3678.

https://doi.org/10.1182/blood.V112.11.3678.3678

Published: 2008

Journal Articles

A Novel Orally Active Small Molecule Potently Induces G1 Arrest in Primary Myeloma Cells and Prevents Tumor Growth by Specific Inhibition of Cdk4/6.

Linda B. Baughn, PhD, Maurizio Di Liberto, PhD, Kaida Wu, PhD, Peter Toogood, PhD, Tracey Louie, Rachel Gottschalk, Ruben Niesvizky, MD, Hearn J. Cho, MD, PhD, Scott Ely, MD, MPH, Malcolm A.S. Moore, D Phil, Selina Chen-Kiang, PhD

Blood (2006) 108 (11): 369.

https://doi.org/10.1182/blood.V108.11.369.369

Published: 2006

Journal Articles

Mutually Exclusive Cdk4-Cyclin D1 and Cdk6-Cyclin D2 Pairing Inactivates Rb and Promotes Cell Cycle Dysregulation in Multiple Myeloma.

Scott Ely, MD, MPH, Maurizio Di Liberto, PhD, Ruben Niesvizky, MD, Eunice Hatada, PhD, Hearn Cho, MD, PhD, Daniel M. Knowles, MD, Joseph Lane, MD, Selina Chen-Kiang, PhD

Blood (2005) 106 (11): 501.

https://doi.org/10.1182/blood.V106.11.501.501

Published: 2005

NARROW

Composite Copy Number Variation in CDK4 , CDKN2A and RB1 Predisposes Mantle Cell Lymphoma to Expansion of PD1+ Tumor Cells and Resistance to CDK4/6 Inhibitor Therapy as Revealed by Integrative Longitudinal scRNA-seq

Disrupting GRINL1A Association with Cereblon Accelerates IKZF1/3 Degradation and IMiD Killing of Mantle Cell Lymphoma Cells By CDK4/6 Inhibition

PRMT5 Inhibition Drives Therapeutic Vulnerability to BCL-2 Inhibition with Venetoclax and Provides Rationale for Combination Therapy in Mantle Cell Lymphoma

T-Cell Clonal Expansion and Activation Associated with Durable Clinical Response to Dual BTK and CDK4/6 Inhibitor Therapy in Mantle Cell Lymphoma

Targeting PRMT5 to Circumvent Acquired Ibrutinib Resistance in Mantle Cell Lymphoma

Cooperative Repression of IRF4 and Induction of IRF7 By CDK4/6 Inhibition Sensitizes Mantle Cell Lymphoma Cells to IMiD-Mediated Apoptosis Independent of p16 Deletion or c-Myc Overexpression

A Phase I Trial of Ibrutinib Plus Palbociclib in Patients with Previously Treated Mantle Cell Lymphoma

PIK3IP1 Inhibition of PI3K in G1 Arrest Induced By CDK4 Inhibition Reprograms MCL for Ibrutinib Therapy

High-Dose Carfilzomib and Dexamethasone As First-Line Treatment in Symptomatic Multiple Myeloma

Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma Overcomes Negative Prognostic Impact of Adverse Cytogenetics and Prior Resistance to Lenalidomide and Bortezomib

Inhibition of CDK4/CDK6 Sensitizes Myeloma to IMiD By Reducing the MEIS2 to Cereblon Ratio That Accelerates IKZF1 and IKZF3 Degradation

Sensitizing shRNA Screen for Molecular Targets in CDK4/CDK6-Based Combination Therapy in Multiple Myeloma

Poor Overall Survival of Patients with Ibrutinib-Resistant Mantle Cell Lymphoma

Protein Arginine Methyltransferase 5 Directly Targets and Epigenetically Silences microRNAs miR33b and miR96 to Support Constitutive Cyclin D1 Activity in Non-Hodgkin’s Lymphoma

Selective inhibition of CDK4/CDK6 sensitizes bone marrow myeloma cells for killing by proteasome inhibitors carfilzomib and PR-047 through cell cycle-dependent expression of pro-apoptotic Noxa and Bim.

Induction of sequential G1 arrest and synchronous S phase entry by reversible CDK4/CDK6 inhibition sensitizes myeloma cells for cytotoxic killing through loss of IRF-4.

Induction of Sustained Early G1 Arrest by Selective Inhibition of CDK4 and CDK6 Primes Myeloma Cells for Synergistic Killing by Proteasome Inhibitors Carfilzomib and PR-047

Selective Inhibition of CDK4 and CDK6 Primes Chemoresistant Myeloma Cell for Cytotoxic Killing through Induction of Cell Cycle-Coupled Mitochondrial Dysfunction and Apoptosis

A Novel Orally Active Small Molecule Potently Induces G1 Arrest in Primary Myeloma Cells and Prevents Tumor Growth by Specific Inhibition of Cdk4/6.

Mutually Exclusive Cdk4-Cyclin D1 and Cdk6-Cyclin D2 Pairing Inactivates Rb and Promotes Cell Cycle Dysregulation in Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only